Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This is one of six new Oxford-Celgene Fellowships, which give postdoctoral researchers exposure to the field of commercial drug discovery and development.

Ruxandra Dafinca
I feel very lucky to have been awarded an Oxford-Celgene Fellowship and I am excited to start working on my project which will hopefully uncover new therapeutic targets involved in neuronal transport defects in ALS.
- Ruxandra Dafinca

The Oxford-Celgene Fellowship Programme was established in 2015 with the aim of stimulating new scientific discovery and translation and to facilitate skills and people transfer between researchers in academia and industry.

Oxford’s relationship with Celgene continues to grow year on year, with the new 2019 Fellowships taking the total of Oxford-Celgene Fellows to 22. The new Fellowships represent an additional investment of £3M into the University.

Ruxandra Dafinca models amyotrophic lateral sclerosis (ALS or motor neuron disease) in neurons obtained by differentiating induced pluripotent stem cells (iPSCs) derived from patients. 

During her three-year research project she will collaborate with Celgene scientists, benefit from mentorship and training, and visit facilities at Celgene labs in the US and Spain.

Ruxandra is interested in a particular mutation found in ALS motor neurons. The protein TDP-43 is found in the wrong compartment of the cell in 97 per cent of ALS cases. She wants to understand what drives this change. Using microscopy and mouse models, she will investigate how transport both in and out of the nucleus, and across the cell, is generally different in patient cells compared to healthy neurons.

In year two of her project, Ruxandra hopes to use her understanding of how the protein is disregulated to begin screening for drugs that are able to restore normal function. She is excited about the potential of this work, which is based on good preliminary data.

Similar stories

Oxford researchers uncover how Parkinson's disease protein damages brain cells

A new study reveals a key mechanism by which the protein alpha-synuclein, the hallmark of Parkinson's disease, damages neurons (brain cells) by blocking a vital cellular gateway. The results of the study, published in Nature Communications, help to explain how the disease begins and highlights a potential new target for treatment.

Silver award for the NDCN Green Impact team

Congratulations to the NDCN Green Impact team who have earned a silver award for their work to improve sustainability within the department.

Celebrating NDCN at Thomas Willis Day 2026

Our annual event where we join together to celebrate our people and the work of our Department over the last year. Nearly 250 staff and students came together for this year's event on Tuesday 16 June at the Mathematical Institute.

New Lancet review calls for urgent action to tackle the growing global threat of encephalitis

The review highlights encephalitis as an urgent global health challenge and calling for faster diagnosis, improved treatments, and strengthened prevention strategies to reduce death and disability worldwide.

Success for NDCN teams at the Vice-Chancellor's Awards 2026

The Vice-Chancellor’s Awards, which recognise achievements and celebrate success across the collegiate University, were announced at a special ceremony hosted by the VC at the Schwarzman’s Sohmen Concert Hall on Thursday 4 June

Dr Ruxandra Dafinca awarded an Alzheimer’s Society Dementia Research Leader Fellowship

Ruxandra Dafinca is one of 17 early career researchers awarded a fellowship in the 2025/2026 call for her project focused on frontotemporal dementia.